Search
for
Sort by
Research
30-60 / 1000+ results
research P07 Pityriasis amiantacea: a unique presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapy
A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.
research Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia)
Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.
research Psoriatic Alopecia in a Patient With Crohn Disease: An Uncommon Manifestation of Tumor Necrosis Factor α Inhibitors
A girl with Crohn's disease developed hair loss due to her increased medication, a rare side effect seen in some children.
research Trichorrhexis nodosa: a distinctive presentation after tumour necrosis factor-α inhibitor therapy
Etanercept may cause hair fragility and breakage.
research Tumor necrosis factor α inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature
Stopping TNFα inhibitors can help children regrow hair lost due to the medication.
research Hair Loss Induced by Tumor Necrosis Factor Alpha Inhibitors
Some drugs used to treat immune conditions may cause different types of hair loss.
research A linear and reticulate crusted keratotic papulopustular eruption: a rare presentation of PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) complex
A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
research Epidermal growth factor receptor inhibitor Geftinib-induced erosive pustular dermatosis of the scalp – A report with a brief review of the literature
Gefitinib can cause scalp skin issues and permanent hair loss.
research - Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia)
Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.
research Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia)
Some drugs for inflammation may cause psoriasis-like hair loss.
research Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study
Diphenylcyclopropenone treatment helps hair growth in alopecia areata by promoting blood vessel growth and cell survival.
research Histone deacetylase inhibitors promote neurosteroid‐mediated cell differentiation and enhance serotonin‐stimulated brain‐derived neurotrophic factor gene expression in rat C6 glioma cells
HDAC inhibitors help brain cells grow and improve brain function.
research Increased Macrophage Migration Inhibitory Factor (MIF) in the Sera of Patients with Extensive Alopecia Areata
Patients with severe alopecia areata have higher levels of MIF, which decrease after successful treatment.
research Serum Level of Macrophage Migration Inhibitory Factor (MIF) in Egyptians With Alopecia Areata and Its Relation to the Clinical Severity of the Disease
Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.
research Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
research Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
research Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
research Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.
research HaCaT‑conditioned medium supplemented with the small molecule inhibitors SB431542 and CHIR99021 and the growth factor PDGF‑AA prevents the dedifferentiation of dermal papilla cells in vitro
A mix of specific inhibitors and a growth factor helps keep hair growth cells from losing their properties in the lab.
research Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib
Erlotinib may cause scarring hair loss.
research BI02 (P97): Epidermal growth factor receptor inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege
research P97: Epidermal growth factor receptor inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege
research Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor
research Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
research Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment
Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.
research Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
Iressa often causes skin issues like acne and dryness in lung cancer patients.
![Discovery of 7-Methoxy-6-[4-(4-Methyl-1,3-Thiazol-2-yl)-1H-Imidazol-5-yl]-1,3-Benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia](/images/assets/9620bd26-3366-4f2a-bcac-f511697bbc41/small/35997.jpg)
research Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
A new compound shows promise as a topical treatment for hair loss.